Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 25–48 of 150
Wisp, a women-focused telehealth platform, has launched a longevity category offering NAD+, glutathione, and low-dose naltrexone through clinician-guided care rather than biohacking positioning. The move addresses a significant gap: 75% of women prioritize long-term health, yet only 11% feel current digital tools provide meaningful control over aging outcomes.
Employers are transitioning from reactive wellness programs to data-driven preventive health strategies as workforces age and the gap between lifespan and healthspan widens. This shift positions HR leaders as active participants in longevity science implementation, though adoption remains uneven and raises substantive questions about data governance, employee trust, and ethical boundaries.
The Buck Institute launched Healthspan Horizons, a federated research initiative that integrates continuous real-world health signals from wearables and lifestyle tracking with periodic deep biological analyses to detect disease risk years before clinical diagnosis. The program positions data density and longitudinal measurement as infrastructure for shifting medicine from reactive treatment to anticipatory intervention.
20/20 BioLabs launched OneTest for Longevity, a blood test combining inflammatory biomarkers, lifestyle data, and AI to identify chronic disease risk before clinical symptoms emerge. The platform translates biomarker patterns into actionable dietary and lifestyle modifications, addressing inflammation and stress response as primary drivers of aging and age-related disease.
Longevitix, a clinical infrastructure platform, addresses the operational gap between diagnostic data abundance and consistent implementation in longevity medicine. Named Technology Partner for The Longevity Show 2026, the system translates multi-source patient data into structured, evidence-aligned clinical recommendations while automating accountability loops between visits.
The 2026 Asia-Pacific Healthy Longevity International Summit will convene over 2,000 global leaders in Hong Kong to advance clinical implementation of longevity science. The event reflects a strategic shift from discovery toward translating research into scalable, real-world health interventions across healthcare systems.
The NUS Geromedicine Conference (February 2026) addresses the translation gap between geroscience mechanisms and clinical application, bringing together researchers, clinicians, and industry to move from pathway discovery to actionable protocols in real-world longevity practice.
Human Longevity has released an AI-powered mobile app that analyzes biometric, lifestyle, and genetic data to generate personalized health recommendations across nutrition, exercise, sleep, and preventive care. The platform's utility depends on the quality of data interpretation and user adherence to recommendations over time.
Agentis Longevity and Ultrahuman have partnered to integrate continuous biosensor data with clinical longevity tracking through the Longevity Quotient (LQ) score, creating real-time health monitoring between clinic visits. The collaboration addresses a critical gap in preventive care: translating isolated health data into actionable patterns that reflect actual lifestyle and physiological changes.
Ambr's explainable AI platform integrates clinical data, biomarkers, and lifestyle information to help primary care physicians identify patient health trajectories and intervene with preventive strategies before disease develops. The approach targets population-level prevention through existing healthcare infrastructure rather than direct-to-consumer channels, addressing the gap between longevity science and routine clinical practice.
Fountain Life launched APEX, a year-long premium membership that integrates full-body diagnostic screening with functional movement assessment and VO₂ max testing to shift from episodic health snapshots to continuous, performance-focused monitoring. This model addresses a gap in longevity medicine: most preventive programs measure biomarkers and imaging but neglect movement quality and cardiorespiratory capacity—the actual mechanics of aging and functional independence.
Vitalist Bay 2026, the world's largest longevity conference, returns to Berkeley May 14–17 with over 60 speakers and workshops spanning aging biology, AI, biotech translation, and investment. The event consolidates leading researchers, entrepreneurs, clinicians, and investors into a four-day intensive focused on accelerating the scientific and commercial infrastructure around human lifespan extension.
A curated education marketplace has launched to address the fragmentation in longevity learning, creating a vetted platform for clinicians, practitioners, and consumers to access high-quality programs that bridge scientific discovery and clinical practice. The platform recognizes that rapid advancement in longevity science has outpaced the development of standardized, accessible training infrastructure.
The Longevity Show launches a 2026 pitch competition for consumer-ready healthspan startups, targeting the critical gap between laboratory discovery and real-world implementation. The competition emphasizes clinical plausibility and measurable impact over marketing hype, reflecting the sector's maturation toward systems-based, scalable prevention rather than isolated interventions.
A 6-month multidomain lifestyle intervention combining nutritional support and supervised exercise slowed epigenetic aging markers and improved physical function in frail adults over 80, with measurable reductions in biological aging indicators. The findings suggest that coordinated lifestyle strategies can alter the trajectory of age-related decline at the molecular level, not merely at the symptomatic level.
As longevity ventures mature from research-driven enterprises to scalable commercial platforms, specialized legal frameworks become essential infrastructure. The establishment of dedicated longevity legal practices signals that regulatory clarity and compliant business model design are now rate-limiting factors for sector growth, not biology itself.
This AMA addresses multiple longevity domains: biological aging biomarkers, exercise protocols for longevity, emerging therapeutic approaches, GLP-1 receptor agonists, and sun exposure risk-benefit profiles. The discussion emphasizes that evidence-based interpretation of these tools requires distinguishing between mechanistic plausibility and demonstrated clinical outcomes.
The global longevity market is projected to exceed $740 billion by 2026, driven by a structural shift toward integrated healthcare platforms combining AI, genomics, and regenerative medicine. This transition reflects movement from consumer wellness toward clinical prevention and early risk detection supported by institutional stakeholders.
Death Clock has launched Life Lab, an AI-driven health concierge that integrates blood biomarker analysis with personalized preventive guidance to help users close the gap between their current and optimized projected lifespan. The service aggregates laboratory testing, medical records, and wearable data to identify actionable interventions across four major chronic disease categories.
Longevity.Technology launched DLT, an AI-driven intelligence platform that aggregates data on over 600 longevity biotech companies, clinical assets, intellectual property, and partnerships into a queryable dataset. This addresses a fragmentation problem in longevity research and investment where critical market intelligence has been scattered across multiple sources.
The inaugural Longevity Show has reached 80% capacity in its partner floor with weeks remaining, signaling that longevity has transitioned from niche to mainstream market category. The event's broad ecosystem—spanning diagnostics, nutrition, fitness, therapeutics, and recovery—reflects how health optimization is increasingly understood as systemic rather than vertical.
The global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven by a shift from reactive disease treatment to preventive health monitoring and consumer-directed self-management. This expansion reflects a fundamental change in how aging is approached—not as an inevitable decline to manage, but as a process to optimize through early detection, biological measurement, and strategic intervention.
Wisp, a telehealth platform owned by WELL Health, launched a longevity care suite offering glutathione, NAD+, and low-dose naltrexone to support cellular energy, immune function, and biological repair in women. The initiative addresses gaps in aging care during perimenopause and menopause through clinician-guided, asynchronous consultations and personalized treatment adjustments.
This article describes a data-driven approach to constructing longevity biotech investment portfolios by mapping public companies to the hallmarks of aging rather than disease labels. The mechanism-first framework enables investors to identify companies with broader pipeline optionality and reduced concentration risk across the fragmented longevity biotech landscape.
